Vocera Expands Clinical Integrations With Electronic Health Records

SAN JOSE, Calif., April 2, 2015 (GLOBE NEWSWIRE) -- Vocera Communications, Inc. (NYSE:VCRA), the leading provider of intelligent, real-time communication and collaboration solutions for mission-critical mobile environments, announced today the introduction of enhanced functionality that enables interactive communications between Electronic Health Record systems (EHR) and the Vocera Communication System. Vocera is pleased to announce compatibility of this new Vocera functionality with Epic's EHR software. This will be the first of several two-way clinical integrations with EHRs, and furthers Vocera's commitment to increasing the level of connectivity between the company's award-winning communication system and clinical systems.

"Real-time communication and collaboration requires robust, two-way integrations between EHRs, clinical systems, and our communication platform," said Brent Lang, CEO of Vocera. "Our unique capabilities and on-going roadmap of integrations between EHRs and Vocera solutions accelerate our customers' ability to deliver better care."

As a result, Vocera worked with Epic to collaborate on a two-way integration for environmental services. This functionality makes it even easier for housekeepers to provide real-time updates for bed cleaning status and availability, therefore improving patient flow.

This innovative technology enables housekeepers to use voice commands on their Vocera device to respond to messages from the EHR in order to update their work status, while also providing time-based data needed for ongoing staff efficiency and workflow performance.

For team members, this new functionality from Vocera will simplify the user's experience and increase the likelihood of more timely updates to the bed management system while providing better visibility for management and helping improve the patient experience. Vocera aims to make these new solutions available for use with a variety of additional EHR providers and additional workflows as customer demand grows.

The company also added the ability to access the Vocera Collaboration Suite directly from the EHR desktop and mobile applications. This maintains communication capabilities with the care team and saves valuable time by reducing the need to manually switch between applications to contact other members of the care team.

To learn more, please visit us in Booth #2012 at the 2015 HIMSS Conference in Chicago from April 12-16, or go to www.vocera.com for more information.

 

About Vocera

Vocera Communications, Inc. [NYSE:VCRA] empowers teams through intelligent, real-time communication and collaboration in healthcare, hospitality, energy, and other mission-critical mobile environments.

Widely recognized for developing smarter ways to communicate, Vocera offers enterprise-class technologies that enable collaboration for mobile teams on their device of choice. Vocera solutions are installed in more than 1,200 organizations worldwide, improving efficiency, quality, safety and outcomes while creating optimal working and healing environments. Via the company's research collaborative, the Experience Innovation Network, Vocera also drives thought leadership for the healthcare industry and new standards in care delivery to elevate patient, family, nurse and physician experiences. Vocera is headquartered in San Jose, California, with offices in San Francisco, Tennessee, Canada, India, United Arab Emirates, and the United Kingdom.

For more information, visit www.vocera.com and @VoceraComm on Twitter.

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.